Retifanlimab-dlwr

(Zynyz®)

Retifanlimab-dlwr

Drug updated on 1/4/2024

Dosage FormInjection (intravenous: 500 mg/20 mL (25 mg/mL) solution in a single-dose vial)
Drug ClassProgrammed death receptor-1 (PD-1)–blocking antibody
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).

Product Monograph / Prescribing Information

Document TitleYearSource
Zynyz (retifanlimab-dlwr) Prescribing Information. 2023Incyte Corporation, Wilmington, DE